You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

CLINICAL TRIALS PROFILE FOR GOLODIRSEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for golodirsen

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02500381 ↗ Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD) Recruiting Sarepta Therapeutics Phase 3 2016-09-28 The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
NCT02500381 ↗ Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD) Recruiting Sarepta Therapeutics, Inc. Phase 3 2016-09-28 The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053 compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
NCT03532542 ↗ An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy Enrolling by invitation Sarepta Therapeutics Phase 3 2018-08-02 The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
NCT03532542 ↗ An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy Enrolling by invitation Sarepta Therapeutics, Inc. Phase 3 2018-08-02 The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
NCT04179409 ↗ A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications Active, not recruiting Sarepta Therapeutics, Inc. Phase 2 2020-02-18 This is an 48-week open-label study to determine the efficacy and safety of casimersen, eteplirsen, or golodirsen for the treatment of boys with duchenne muscular dystrophy who have a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly infusions and two muscle biopsies at baseline and at month 12.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for golodirsen

Condition Name

Condition Name for golodirsen
Intervention Trials
Duchenne Muscular Dystrophy 4
DMD 1
Muscular Dystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for golodirsen
Intervention Trials
Muscular Dystrophy, Duchenne 4
Muscular Dystrophies 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for golodirsen

Trials by Country

Trials by Country for golodirsen
Location Trials
United States 44
Spain 3
Belgium 3
Canada 3
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for golodirsen
Location Trials
Georgia 3
Pennsylvania 3
Ohio 3
Oregon 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for golodirsen

Clinical Trial Phase

Clinical Trial Phase for golodirsen
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for golodirsen
Clinical Trial Phase Trials
Active, not recruiting 1
Enrolling by invitation 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for golodirsen

Sponsor Name

Sponsor Name for golodirsen
Sponsor Trials
Sarepta Therapeutics, Inc. 4
Sarepta Therapeutics 2
Kevin Flanigan 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for golodirsen
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.